Alkermes Overview

  • Founded
  • 1987
Founded
  • Status
  • Public
  • Employees
  • 2,235
Employees
  • Stock Symbol
  • ALKS
Stock Symbol
  • Investments
  • 13
  • Share Price
  • $18.43
  • (As of Wednesday Closing)

Alkermes General Information

Description

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

Contact Information

Formerly Known As
Antler Science Two
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Stock Exchange
NAS
Primary Office
  • Connaught House
  • 1 Burlington Road
  • Dublin D04 C5Y6
  • Ireland
+353 (01) 000 0000
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Alkermes Stock Performance

(As of Wednesday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$18.43 $18.37 $11.98 - $21.86 $2.92B 159M 1.27M -$0.46

Alkermes Financials Summary

In Thousands,
USD
TTM 30-Sep-2020 FY 2019 31-Dec-2019 FY 2018 31-Dec-2018 FY 2017 31-Dec-2017
EV 2,493,573 2,919,237 4,398,109 8,248,051
Revenue 1,171,491 1,170,947 1,094,274 903,374
EBITDA 25,460 (117,018) (17,108) (37,392)
Net Income (73,573) (196,620) (139,311) (157,945)
Total Assets 1,876,820 1,805,403 1,825,007 1,797,227
Total Debt 385,598 290,946 279,308 281,436
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Alkermes Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, d
Pharmaceuticals
Dublin, Ireland
2,235 As of 2019
00.000
000000000 00.000

0000 000

iquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum
000000000000000
Monmouth Junction, NJ
000 As of 0000
000000000 -

00000000

e et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut
000000000000000
Ingelheim am Rhein, Germany
00000 As of 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Alkermes Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tris Pharma Private Debt Financed Monmouth Junction, NJ 000 000000000 -
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
000000000000000 Corporation Brentford, United Kingdom 00000 00000000000
000000 00000000 Corporation Tokyo, Japan 00000 00.000 00000000 00.000
0000000000 0000000 Corporation San Francisco, CA 000 000000&0
You’re viewing 5 of 30 competitors. Get the full list »

Alkermes Executive Team (31)

Name Title Board Seat Contact Info
Richard Pops Chief Executive Officer & Chairman
James Frates Chief Financial Officer, Finance & Senior Vice President
Michael Landine Senior Vice President, Corporate Development
Shannon Smith Director, Benefits and HRIS
Michael Koch Director, Clinical Supply Chain
You’re viewing 5 of 31 executive team members. Get the full list »

Alkermes Board Members (11)

Name Representing Role Since
David Anstice Self Board Member 000 0000
Frank Wilson Self Board Member 000 0000
Nancy Wysenski Self Board Member 000 0000
Paul Mitchell Self Board Member 000 0000
Richard Gaynor Self Board Member 000 0000
You’re viewing 5 of 11 board members. Get the full list »

Alkermes Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Alkermes Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Alkermes‘s full profile, request access.

Request a free trial

Alkermes Investments & Acquisitions (13)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 000000000000 25-Nov-2019 000000000000000000 00000 Drug Discovery 00000 000000000 00
0000000 0000000000 25-Aug-2014 00000 00000 00 0000 Drug Delivery 000000 000000 00
0000000000000 0000 26-Nov-2013 00000 00000 00 000.00 Discovery Tools (Healthcare) 00000 0000000
0000000 0000000000 11-Sep-2013 00000 00000 00 0000 Drug Delivery 000000 000000 00
Acceleron Pharma 23-Dec-2011 Later Stage VC 000.00 Biotechnology 0000000 0000
You’re viewing 5 of 13 investments and acquisitions. Get the full list »

Alkermes Exits (7)

Company Name Exit Date Exit Type Exit Size Status Buyers
0000000 0000000000 25-Aug-2014 00000 00000 00 0000 Completed
  • 12 buyers
0000000 0000000000 11-Sep-2013 00000 00000 00 0000 Completed
  • 6 buyers
000000000 000000 23-Dec-2011 00000 00000 00 000.00 Completed
  • 15 buyers
0000000 0000000000 12-Jul-2011 00000 00000 00 0000 Completed
  • 4 buyers
Acceleron Pharma 15-Dec-2009 Corporate 0000 Completed
You’re viewing 5 of 7 exits. Get the full list »